DelMar Pharmaceuticals Profile

USD 0.001  0.0927%

Conversion by Dennis Brown of 24000 shares of DelMar Pharmaceuticals

DelMar Pharmaceuticals Inc insider trading alert for conversion of warrants (right to buy) by Dennis Brown, Chief Scientific Officer, on March 8, 2018. This event was filed by Delmar Pharmaceuticals In with SEC on 2013-08-06. Statement of changes in beneficial ownership - SEC Form 4. Dennis Brown is currently serves as chief scientific officer, director of DelMar Pharmaceuticals [view details]   

DelMar Pharmaceuticals Summary

DelMar Pharmaceuticals Inc (DMPI) is traded on Nasdaq Capital Markets in USA. It is located in BRITISH COLUMBIA, CANADA and employs 4 people. DelMar Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Micro-Cap' category with current market capitalization of 23.46 M. DelMar Pharmaceuticals Inc conducts business under Healthcare sector and is part of Pharmaceutical Products industry. This company has 21.93 M outstanding shares of which 1.25 M shares are currently shorted by private and institutional investors with about 2.21 trading days to cover. DELMAR PHARMA currently holds about 11.02 M in cash with (9.46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.5.
Check DelMar Pharmaceuticals Probability Of Bankruptcy

Ownership Allocation (%)

Top Holders

DelMar Pharmaceuticals Risk Profiles

Key Fundamentals

DelMar Pharmaceuticals Against Markets

Current Ratings

DelMar Pharmaceuticals 30 Days Performance Scores
Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
< 90% 
Equity ratings for DelMar Pharmaceuticals Inc are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
DelMar Pharmaceuticals, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients who have failed to respond to modern therapy. DelMar Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Vancouver, Canada. DelMar Pharmaceuticals operates under Biotechnology classification in USA and traded on Nasdaq Capital Markets. It employs 4 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameDelMar Pharmaceuticals Inc
President CEO, DirectorJeffrey BachaView All
Thematic Classifications
Analyst Consensus
Macroaxis Advice
InstrumentUSA Stock View All
Business Address999 West Broadway
ExchangeNasdaq Capital Markets
IndustryPharmaceutical Products
Contact Number604 629 5989
CurrencyUSD - US Dollar


DelMar Pharmaceuticals Analyst Recommendations
Target PriceAdvice# of Analysts
14.84Strong Buy5Odds
DelMar Pharmaceuticals Inc current and past analyst recommendations published by number of research institutions as well as average analyst consensus
DelMar Pharmaceuticals Analyst Advice  


Explore Investment Opportunities
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Investing Ideas  


DelMar Pharmaceuticals Earnings Estimates
EPSEstimate Date
Quarterly Estimate-0.17February 21, 2017
DelMar Pharmaceuticals Inc normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  


DelMar Pharmaceuticals Corporate Directors
John Bell Independent Director
William Garner Director
Erich Mohr Independent Director